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I. INTRODUCTION
From human androids to robot surgeons, a dystopian world
with technology dominating every aspect of life may be closer to reality
than fiction. For instance, in 2017, Saudi Arabia granted citizenship to
a humanoid robot named Sophia for the first time in history.1 Built by
the Hong Kong-based company, Hanson Robotics, Sophia is imbued
with artificial intelligence and can reportedly mimic sixty-two human
facial expressions.2 After being given the gift of legal personhood,
Sophia has now been condemned to an eternity of working in
marketing.3 Naturally, this event has triggered discussions among
scholars and laypeople on the ethics of artificial intelligent humanoids.4
Another example involves the da Vinci robotic system, introduced by

Alistair Walsh, Saudi Arabia Grants Citizenship to Robot Sophia, DEUTSCHE
WELLE (Oct. 28, 2017), https://www.dw.com/en/saudi-arabia-grants-citizenshipto-robot-sophia/a41150856#:~:text=Saudi%20Arabia%20granted%20citizenship%20to,company%2
0Hanson%20Robotics%20in%202015.
2 Id.
3
Emily Reynolds, The Agony of Sophia, the World’s First Robot Citizen Condemned
to
a
Lifeless
Career
in
Marketing, WIRED (June
1,
2018),
https://www.wired.co.uk/article/sophia-robot-citizen-womens-rights-detriotbecome-human-hanson-robotics.
4 Id.
1
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Intuitive Surgical in 2000.5 In the past twenty years, researchers have
designed automation builds that can be tacked onto the existing da
Vinci system to allow for greater automation during surgical
procedures.6 Currently, these robot surgeons are conducting
procedures that include bone cuts and radiation delivery for cancer
treatment.7
Artificial intelligence and machine learning have already
dominated many aspects of human lives, but they often go unnoticed
as these applications have integrated so smoothly into human society.
Because of the ability of artificial intelligence and machine learning
applications to self-learn and imitate the traits of the human mind—
like reasoning, problem solving, planning, and optimal decisionmaking—many industries implementing such technologies have
thrived.8 One of the most significant advancements in this space is in
the healthcare industry with the development of software as a medical
device (SaMD).9
The International Medical Device Regulators Forum (IMDRF)
defines the term “software as a medical device” (SaMD) as “software
intended to be used for one or more medical purposes that perform
these purposes without being part of a hardware medical device.”10
The IMDRF is a voluntary world-wide group of medical device
regulators who have come together to harmonize medical device

5 About da Vinci Systems, INTUITIVE, https://www.davincisurgery.com/davinci-systems/about-da-vinci-systems (last visited Feb. 6, 2021).
6 Id.
7
Elizabeth Svoboda, Your Robot Surgeon Will See You Now, NATURE (Sept.
25, 2019), https://www.nature.com/articles/d41586-019-02874-0.
8
Suni Kumar, Advantages and Disadvantages of Artificial Intelligence, TOWARDS
DATA SCI. (Nov. 25, 2019), https://towardsdatascience.com/advantages-anddisadvantages-of-artificial-intelligence-182a5ef6588c.
9
IMDRF SaMD Working Group, Software as a Medical Device (SaMD): Key
Definitions, INT’L MED. DEVICE REG. F.,
4
(Dec.
9,
2013),
http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-131209-samd-keydefinitions-140901.pdf.
10 Id. at 6.
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regulation.11 IMDRF develops internationally agreed upon documents
related to a wide variety of topics affecting medical devices.12 In 2013,
IMDRF formed the Software as a Medical Device Working Group
(WG) to “develop guidance supporting innovation and timely access
to safe and effective Software as a Medical Device globally.”13
The U.S. Food and Drug Administration (FDA) and the
European Commission (EC) are responsible for promulgating
regulations for all types of medical devices.14 Healthcare industry
technology is ever-evolving and inventors are continually innovating
new ways to use software as medical devices, specifically artificial
intelligence (AI) and machine learning (ML)-based medical devices.15
These software applications have benefitted the healthcare industry,
improving diagnostic efficacy and efficiency in medical monitory and
healthcare administration.16 Although regulatory agencies around the
world have adapted to SaMD, the integration of AI/ML algorithms
into a medical device is still emerging.

11 International Medical Device Regulators Forum (IMDRF), U.S. FOOD & DRUG
ADMIN. (Aug. 27, 2019), https://www.fda.gov/medical-devices/cdrh-internationalprograms/international-medical-device-regulators-forum-imdrf.
12 Id.
13 Software as a Medical Device (SaMD), U.S. FOOD & DRUG ADMIN. (Dec. 4,
2018),
https://www.fda.gov/medical-devices/digital-health-centerexcellence/software-medical-device-samd (discussing role of Software as a Medical
Device Working Group, chaired by the FDA, to create framework for risk
categorization, quality management system, and clinical evaluation of Software as a
Medical Device).
14
NATIONAL ACADEMIES PRESS (US), PUBLIC HEALTH EFFECTIVENESS
OF THE FDA 510(K) CLEARANCE PROCESS: BALANCING PATIENT SAFETY AND
INNOVATION: WORKSHOP REPORT 35-41 (Wizemann T ed., 2010) (providing an
introduction to the medical device framework in the European Union and comparing
with medical device frameworks in Japan, India, and China).
15
Alicia Phaneuf, Use of AI in Healthcare & Medicine Is Booming – Here’s How
the Medical Field Is Benefiting from AI in 2021 and Beyond, INSIDER (Jan. 29, 2021, 8:47
PM),
https://www.businessinsider.com/artificial-intelligencehealthcare#:~:text=save%20them%20money.,AI%20has%20the%20ability%20to%20analyze%20big%20data%20sets%20%E2
%80%93%20pulling,AI%20to%20better%20serve%20patients.
16
Phaneuf, supra note 15.
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There are two main concerns for AI/ML-based medical device
inventions: the lack of regulations in the United States and European
Union (EU) and the need for invention novelty to cross the
patentability threshold.17 When implemented appropriately, medical
device regulations provide robust protection for public health, which
enables the public to have access to safe and effective medical
treatment.18 Also, exclusive patent rights allow inventors to
strategically exclude others from making, using, or selling their
invention in the issuing country during the life of the patent, allowing
patent holders leverage over emerging competition.19 Both of these
considerations are crucial for positive outcomes of AI/MI based
inventions in the medical technology industry. Consequently,
regulatory bodies have the crucial job of creating AI/ML regulations
that will address these concerns.
The FDA does not currently have any final regulations relating
to AI/ML in medical devices; the agency only has a proposed
regulatory framework published in discussion papers or guidance
documents for the industry.20 For instance, on April 2, 2019, the FDA
published a discussion paper and requested feedback on the Proposed
Regulatory Framework for Modifications to Artificial Intelligence/Machine
Learning (AI/ML)-Based Software as a Medical Device (SaMD).21 Similarly,
Christian Johner, Artificial Intelligence in Medicine, JOHNER INST. N.
AMERICA (Feb. 2, 2019), https://www.johner-institute.com/articles/software-iec62304/and-more/artificialintelligence/#:~:text=There%20are%20currently%20no%20laws,performance%20
of%20the%20medical%20device.
18 Medical Device Regulations: Global Overview and Guiding Principles, WORLD
HEALTH ORG. (2003).
19
Joseph G. Hadzima, The Importance of Patents: It Pays to Know Patent Rules,
BOS. BUS. J. (2005), http://web.mit.edu/e-club/hadzima/the-importance-ofpatents.html.
20
Johner, supra note 17.
21 Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine
Learning (AI/ML)-Based Software as a Medical Device (SaMD), U.S. Food and Drug
Administration
(2019),
http://med.a51.nl/sites/default/files/pdf/Proposed_Regulatory_Framework_for_
Modifications_to_Artificial_Intelligence_Machine_Learning_%28AI_ML%29Based_Software_as_a_Medical_Device_%28SaMD%29__Discussion_Paper_and_Request_for_Feedback.pdf (last visited Apr 15, 2022) (in
the framework described in the discussion paper, the FDA envisions a
17
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the EU has not published any regulations or guidance documents
relating to AI/ML in medical devices,22 which, like those regulations
for hardware medical devices, are crucial in determining the device
safety and efficacy. Through established regulations, manufacturers
and regulators can ensure performance consistency and deliver safe,
effective medical devices to consumers. Based upon current guidance
documents and literature, this article will propose AI/ML-based
medical device regulations for the United States and the EU.23
Before discussing needed regulations, this article first discusses
the general framework of FDA regulations and the EU regulations.
Many countries follow these two regions’ lead when designing medical
device regulations; thus, understanding their specific frameworks is
essential when considering potential harmonization of regulations.
Next, the article will compare the FDA medical device regulations with
the EU medical device regulations. Understanding and comparing the
regulations are critical to comprehend patentability because, in order
for medical devices to be cleared for commercialization or approved
for market, manufacturers need to use a “substantial equivalence”
standard in the United States and an “equivalent device” standard in
the EU.24 These standards impact the U.S. and EU patentability laws
“predetermined change control plan” in premarket submissions. This plan would
include the types of anticipated modifications—referred to as the “Software as a
Medical Device Pre-Specifications”—and the associated methodology being used to
implement those changes in a controlled manner that manages risks to patients —
referred to as the “Algorithm Change Protocol.”).
22
Johner, supra note 17.
23
Originally, the Medical Device Directive (93/42/EEC) was in effect until
the European Commission introduced the EU Medical Device Regulations (EU
2017/745) on May 26, 2017. The European Commission has given the industry three
years for full Medical Device Regulations compliance. Even with the new regulations,
the EC has not introduced any provisions related to artificial intelligence or machine
learning. Transition Timelines from the Directives to the Regulations, EUROPEAN COMM’N,
https://ec.europa.eu/health/sites/health/files/md_newregulations/docs/md_info
graphic-timeline_en.pdf (last visited Feb. 11, 2021)
24
The FDA describes the substantial equivalence standard in an FDA
guidance document. See Section II Background for the definition of “substantial
equivalence.” The EU MDR describing equivalent device. See Section II Background
for the definition of “equivalent device.” It is also important to note that the
substantial equivalence standard is used for Class II medical devices in the United
States; and, the equivalent device standard can be applied as long as the device is
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because it is unclear whether these medical devices, although ready for
commercialization, are novel or inventive enough to get over the
threshold for patentability.
After the patentability discussion, the article will employ a
comparative analysis of U.S. and EU software as a medical device
regulations. Since artificial intelligence and machine learning in the
healthcare space are relatively new, there are not many regulations
relating to AI/ML-based SaMD. Currently, the FDA only has guidance
documents related to AI/ML-based SaMD, but no final promulgated
regulations.25 The EU recently published its new Medical Device
Regulations (MDR), but the MDR only has provisions for general
SaMD, and has not included any provisions relating specifically to
AI/ML-based SaMD.26
Part III Section B of this article will propose potential
pathways for AI/ML-based SaMD regulations for the U.S. and EU
regulatory network. The proposal will be made by comparing the FDA
with EC SaMD regulations and extrapolating that to include AI/MLbased SaMD regulations, while discussing clinical validity of a medical
device with AI/ML.27 Because the FDA also does not have any
regulations specifically for AI/ML and only guidance documents, the
extrapolation for potential regulatory pathways will consider FDA
guidance documents and literature as well.
The last central point of the article will connect AI/ML-based
SaMD regulations back to the patentability issues in the United States
used for the same clinical condition or purpose and has the same kind of user. Only
these types of devices will be considered in this article as that ties into the issues with
patentability.
25 Artificial Intelligence and Machine Learning in Software as a Medical Device, U.S.
FOOD & DRUG ADMIN., https://www.fda.gov/medical-devices/software-medicaldevice-samd/artificial-intelligence-and-machine-learning-software-medical-device
(last updated Jan. 12, 2021) (draft guidance document published by the FDA to
provide information to the industry regarding medical devices that contain artificial
intelligence or machine learning).
26 Transition Timelines from the Directives to the Regulations, supra note 23.
27
Although only clinical validity is mentioned there, the medical device
pathway to commercialization includes submission of technical documentation. This
is further explained in Part II Section C.
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and EU, as discussed in Part III Section C. In addition to
commercialization success, many manufacturers are interested in
obtaining intellectual property rights for their invention. When
manufacturers use the substantial equivalence or the equivalent device
standard, they generally have a hard time finding a novelty hook to
pass the patentability test.28 This challenge is true for all medical
devices, regardless of their mode of operation—hardware or software.
This follows that because the functionality, the clinical validity, and the
intended use of the AI/ML-based SaMD would still be used to
determine whether the device will get cleared or approved for
commercialization, the impact on patentability will still be similar.
Lastly, this article will conclude by providing proposals on how
companies can overcome the challenging patentability hurdle for
AI/ML-based SaMD.
II. BACKGROUND
A. Short History of Artificial Intelligence (AI)
Over the past few decades, the terms “artificial intelligence”
and “machine learning” have become more colloquial with the
technological advancement.29 Software, or more specifically, a piece of
programming algorithm, is a preset, rigid, coded step-by-step
instruction that gets executed when it encounters a trigger.30 On the
other hand, artificial intelligence is a group of algorithms that has the
capability to modify itself and create new algorithms in response to
learned inputs and data.31 Instead of relying on inputs that the standard
algorithm is designed to recognize, “intelligent” algorithms absorb
massive amounts of data and “learn” from the data to form new and
more efficient pathways, similar to human intelligence.32 This capability
35 U.S.C.A. § 101–3 (West 2021).
AMEET V. JOSHI, MACHINE LEARNING AND ARTIFICIAL
INTELLIGENCE 3-7 (1 ed. 2020).
30
Kaya Ismail, AI vs. Algorithms: What’s the Difference?, CMS WIRE (Oct. 26,
2018),
https://www.cmswire.com/information-management/ai-vs-algorithmswhats-the-difference/.
31
Ismail, supra note 30.
32 What Is Artificial Intelligence?, BUILT IN, https://builtin.com/artificialintelligence (last visited Oct. 13, 2020).
28
29
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to change, adapt, and learn based on new data is described as
“intelligence.”33
In 1950, English mathematician Alan Turing, the “Father of
Artificial Intelligence,” published an academic paper titled
“Computing Machinery and Intelligence,” which introduced a concept
that changed the entire world of computer science.34 He developed a
test (the Turing test) that would evaluate a machine’s ability to exhibit
intelligent behavior as either equivalent to or indistinguishable from a
human.35 During the test, a human evaluator would judge a natural
language conversation between a human and a machine.36 If the human
evaluator was unable to distinguish the human from the machine, the
machine was said to have passed the Turing test.37 This test was only
theoretical, but with the increase in computational power over the
decades, intelligent machines are slowly becoming a reality.
The term “artificial intelligence” was first coined in 1956 by
John McCarthy in an academic conference.38 John McCarthy, who
invented the programming language Lisp (historically LISP), organized
a conference with many other experts in the field to discuss the
possibility of machines simulating the human way of thinking.39 Over
the next few decades, as computer processing power increased, the
machines will become more “intelligent,” although expectations for AI
have always exceeded reality.40 While computer software have beaten
humans in chess games and complicated board games, AI has not
advanced enough to simulate human thinking, and no computer has
come close to passing the Turing test.41 Instead of truly intelligent
humanoids as seen in science fiction, AI has a more subtle effect in the
Ismail, supra note 30.
Chris Smith et al., The History of Artificial Intelligence, HISTORY OF
COMPUTING
(Dec.
2006),
https://courses.cs.washington.edu/courses/csep590/06au/projects/history-ai.pdf;
Alan Turing, Computing Machinery and Intelligence, 59 MIND 433-442 (1950).
35 Id. at 433-42.
36 Id.
37 Id.
38
TOM TAULLI, ARTIFICIAL INTELLIGENCE BASICS 6 (1 ed. 2019).
39 Id. at 7.
40 Id. at 8; Id. at 11.
41
Taulli, supra note 38.
33
34
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real world— mostly through automation of mundane tasks to make
human life more efficient.
This is not to say that the field of artificial intelligence is not
advancing rapidly— computers are getting higher processing speeds,
so the progress of artificial intelligence is also accelerating.42 Currently,
many companies utilize artificial intelligence applications to increase
their operations efficiency and reliability. From chatbots to human
resource data management, AI is successfully incorporated into
various business interfaces to help business owners understand how
they receive and interpret data.43
B. Merging Artificial Intelligence and Healthcare
Artificial intelligence is rapidly growing in healthcare,
significantly impacting every aspect of the industry. Introducing
artificial intelligence into the healthcare industry has provided many
advantages for primary healthcare providers, including improving
efficiency, accuracy, and precision of healthcare services.44 Advantages
can also be seen on the healthcare administration side with patient data
management and automating administrative tasks.45 Thirty percent of
healthcare costs are associated with administrative tasks.46 AI can
automate some of these tasks and ease the workload of healthcare
professionals to ultimately save them money.47 Wearable healthcare
technology, like smartwatches, also use AI to better serve patients by

Matt Asay, Where AI Has Made Real Progress, InfoWorld (2021),
https://www.infoworld.com/article/3635489/where-ai-has-made-realprogress.html (last visited Apr 15, 2022).
43
Forbes Technology Council, 15 Business Applications For Artificial Intelligence
And
Machine
Learning,
FORBES
(Sep.
27,
2018),
https://www.forbes.com/sites/forbestechcouncil/2018/09/27/15-businessapplications-for-artificial-intelligence-and-machine-learning/.
44
Amisha et al., Overview of Artificial Intelligence in Medicine, 8(7) J. FAM. MED.
& PRIMARY CARE 2328, 2329 (2019).
45 Id. at 2330.
46
Phaneuf, supra note 15.
47
Id.
42
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analyzing data to alert users and their healthcare professionals of
potential health issues and risks.48
Although AI integration has many advantages, many believe
that AI will eventually replace human workers.49 Their fear is not
entirely unfounded.50 Healthcare professionals may be replaced with
the increasing intelligence in machines.51 Radiologists and pathologists
may be especially vulnerable as many of the most impressive
breakthroughs in AI are happening around medical imaging and
diagnostics.52 Although this fear may be legitimate in certain regions of
the world, many countries are experiencing a shortage of healthcare
professionals, and AI solutions may be a lifesaving option.53 AI can
likely fill worker shortage gaps by reducing menial tasks that healthcare
professionals will have to perform.54 Additionally, introducing AI to
carry out administrative tasks will allow current healthcare
professionals to have more face time with their patients and improve
the patient care experience.55
Data privacy is also one of the most cited concerns regarding
AI healthcare integration.56 The success of AI relies on the wealth of
patient data fed into the algorithms.57 Therefore, data security and
privacy will always be a concern.58 According to a 2017 study
completed in the United Kingdom, the three main types of breaches
in the health sector were (1) data posted or faxed to an incorrect
recipient, (2) loss or theft of paperwork, and (3) data sent by email to

Id.
Jennifer Bresnick, Arguing the Pros and Cons of Artificial Intelligence in
Healthcare,
HEALTH
IT
ANALYTICS
(Sept.
18,
2018),
https://healthitanalytics.com/news/arguing-the-pros-and-cons-of-artificialintelligence-in-healthcare.
50 Id.
51 Id.
52 Id.
53 Id.
54 Id.
55
Id.
56 Id.
57 Id.
58 Id.
48
49
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an incorrect recipient.59 This study suggests that data breaches occur
as a result of accidental mistakes made during the course of routine
care.60 However, government agencies are rapidly catching up to the
advancement of AI technology, and as a result, there has been a surge
in new policies and regulations for data privacy and security.61 The
advancement of AI technology has shown to be advantageous to the
healthcare industry. Instead of impeding its progress, humans will be
forced to learn, change, and adapt, just like artificial intelligent
algorithms.
Three major fields present significant trends in AI: chronic
diseases management, medical imaging, and AI and the Internet of
Things (IoT).62 Through the implementation of machine learning in
AI, companies are able to manage chronic diseases by monitoring the
disease with sensors and automating delivery of treatment as needed
using connected mobile applications.63 The field of medical imaging is
growing with the integration of AI-driven platforms in medical
scanning devices to improve image clarity and clinical outcomes by
reducing radiation exposure.64 Various companies are also integrating
AI and IoT to better monitor patient adherence to treatment protocols
and to improve clinical outcomes.65 As discussed above, unfortunately,
with the prevalence of improved and automated systems, there arises
the concern of decreased job opportunities for humans.66

59 What Are the Risks Around Patient Data?, UNDERSTANDING PATIENT
DATA, https://understandingpatientdata.org.uk/weighing-up-risks#data-breachesin-the-health-sector (last visited Jan. 15, 2021).
60 Id.
61
Bresnick, supra note 49.
62
Kumba Sennaar, AI in Medical Devices—Three Emerging Industry Applications,
EMERJ, https://emerj.com/ai-sector-overviews/ai-medical-devices-three-emergingindustry-applications/. (last updated Nov. 22, 2019).
63
Sennaar, supra note 62.
64
Id.
65
The term Internet of Things (IoT) encompasses everything connected to
the internet, used to define objects that “talk” to each other. Matt Burgess, What Is
the Internet of Things? WIRED Explains, WIRED (Feb. 16, 2018),
https://www.wired.co.uk/article/internet-of-things-what-is-explained-iot.
66
Amisha et al., supra note 44.
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Similar to how the private industry adapts to emerging
technology, regulatory agencies across the globe are discussing how to
implement a regulatory framework for artificial intelligence.67 Public
safety and device efficacy continue to be the priority of many
agencies.68 Regulatory bodies will have to balance safety and efficacy
without impeding the innovation efforts of manufacturers. Further,
regulators around the world recognize the need for a common
regulatory framework and uniform SaMD principles that will promote
safe innovation and protect patient safety.69 With the rapid
development of AI, FDA and EU regulations have not kept pace and
must be addressed for current and future medical device
manufacturers. The FDA and the EU already recognize stand-alone
software as a medical device (SaMD), therefore, it is reasonable to
envelope artificial intelligence within SaMD regulations.70
The United States and EU are two of the five founding
members of the Global Harmonization Task Force (GHTF).71 The
GHTF was founded in 1992 in response to a need for ease of medical
device commercialization without administrative redundancy like
documentation review and repeated safety testing.72 This voluntary
group was comprised originally of representatives from the medical
device regulatory authorities of the five founding members: United
States, European Union, Japan, Australia, and Canada.73 Because major
software companies like Amazon, Oracle, Google, and Facebook are
also based in the United States and the EU, these two regions have a
higher stake in designing favorable medical device regulations.74

Johner, supra note 17.
Id.
69 International Medical Device Regulators Forum (IMDRF), supra note 11.
70 Software as a Medical Device (SaMD), supra note 13; Regulation 2017/745 of
the European Parliament and of the Council of Apr. 5, 2017, art. 2, 2017 O.J. (L 117)
1 (EU).
71
Susan Lamph, Regulation of Medical Devices Outside the European Union,
105(Suppl 1) J. ROYAL SOC’Y MED. S12, S13 (2012).
72 Id.
73 Id.
74 Global
100 Software Leaders by Revenue (2016), PWC (2016),
.https://www.pwc.com/gx/en/industries/technology/publications/global-100software-leaders/explore-the-data.html.
67
68
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C. United States Food and Drug Administration (FDA) Medical
Device Regulation Structure
The U. S. Food and Drug Administration (FDA) is the oldest
comprehensive consumer protection government agency.75 The FDA
promotes and protects the health of the citizens of the country by
regulating food, cosmetics, drugs (including generic drugs and animal
drugs), biologics, and medical devices.76 The agency is split into various
offices that specialize in various product regulation.77 Each office is
responsible for regulating products and ensures that the product is
ready for commercialization.78 FDA’s Center for Devices and
Radiological Health (CDRH) regulates medical devices in the United
States79 by evaluating the safety and efficacy of medical devices before
and after commercialization.80
Under Section 201(h) of the Federal Food, Drug, and
Cosmetics Act,81 FDA defines a medical device as “an instrument,
apparatus, machine, implant, in vitro reagent, including component,
part, or accessory, that diagnoses, cures, mitigates, treats, or prevents
disease or condition, affects structure or function of body, and does
not achieve that purpose as a drug.”82 The agency classifies devices
Elias Mallis, An Introduction to FDA’s Regulation of Medical Devices, U.S.
FOOD & DRUG ADMIN., https://www.fda.gov/media/123602/download (last
visited Oct. 16, 2020).
76 Id.
77 Id.
78 Id.
79
Id..
80 Id.
81
Federal Food, Drug, and Cosmetics Act § 201(h), 21 U.S.C. § 321(h).
82
21 U.S.C.A. § 321(h) (West 2021). FDA defines a medical device as “an
instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent,
or other similar or related article, including a component part or accessory which is:
recognized in the official National Formulary, or the United States Pharmacopoeia,
or any supplement to them, intended for use in the diagnosis of disease or other
conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or
other animals, or intended to affect the structure or any function of the body of man
or other animals, and which does not achieve its primary intended purposes through
chemical action within or on the body of man or other animals and which is not
dependent upon being metabolized for the achievement of any of its primary
intended purposes.”
75
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based on the their description and intended use.83 The classes of
medical devices include Class I, Class II, and Class III; the classes
increase with the degree of risk.84 Devices can also be defined by their
three-letter product codes, which designate groups of similar devices
and intended use.85 This article focuses on Class II devices as the
substantial equivalence standard is only used for Class II medical
devices in the United States; the equivalent device standard can be
applied as long as the device is used for the same clinical condition or
purpose and has the same kind of user.86 Only these types of devices
will be considered in this article as that ties into the issues with
patentability.
Class II medical devices are cleared for commercialization
through two different pathways—a 510(k) submission or an
exemption.87 A 510(k) is a premarket submission made to FDA to
demonstrate that the device to be marketed is as safe and effective,
that is, substantially equivalent, to a legally marketed device.88
Manufacturers must compare their device to one or more similar
legally marketed devices and make and support their substantial
equivalence claims.89 A device is substantially equivalent if,
in comparison to a predicate, it has the same intended
use as the predicate; has the same technological
characteristics as the predicate; or has different
technological characteristics but does not raise
different questions of safety and effectiveness; and the
information submitted to FDA demonstrates that the

Classify Your Medical Device, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/overview-device-regulation/classify-yourmedical-device (last updated Feb. 7, 2020).
84 Id.
85
21 C.F.R. § 807.100 (2020).
86 See note 24.
87 Classify Your Medical Device, supra note 83.
88
Federal Food, Drug, and Cosmetics Act § 513(i)(1)(A).
89 Premarket
Notification 510(k), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/premarket-submissions-selecting-andpreparing-correct-submission/premarket-notification-510k (last updated Mar. 13,
2020).
83
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device is as safe and effective as the legally marketed
device.90
The submission exemption pathway is where devices can be
placed on the market without any formal 510(k) submission to the
FDA due to their low-risk intended use.91 This exemption applies if
the FDA determines that a 510(k) is not required to provide reasonable
assurance of safety and effectiveness for the device.92 Devices which
may be exempt from 510(k) requirements are pre-amendment devices,
and Class I and Class II devices specifically exempted by the FDA.93
The 510(k) pathway may seem like an attractive pathway for
new medical device manufacturers, but several issues have been
identified within the industry.94 The main issue involves the lack of
clarity and consistency of the substantial equivalence standard,
specifically the definitions of “same intended use” and “same
technological characteristics.”95 The intended use of a device and its
labeled indication are usually not synonymous.96 With the absence of a
statutory definition of “same intended use,” the FDA permits a rather
90
The requirements of the 510(k) submission include submission of bench
testing data, non-clinical data, technological documentation, verification and
validation reports, product labeling, and sometimes clinical data may even be
required. Premarket Notification 510(k), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/premarket-submissions/premarketnotification-510k (last updated Mar. 13, 2020).
91 Classify Your Medical Device, supra note 83.
92 Class
I / II Exemptions, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/medical-devices/classify-your-medical-device/class-i-iiexemptions (last updated July 1, 2019).
93
Preamendment status can be obtained for a medical device if it was in
commercial distribution before May 28, 1976, the date the Medical Device
Amendments were signed into law. The FDA requires supporting documentation
and a signed affidavit to prove the preamendment status of a device for a specific
use.
Preamendment
Status,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/medical-devices/quality-and-compliance-medicaldevices/preamendment-status (last updated Nov. 15, 2017); Class I / II Exemptions,
supra note 92.
94
Jonas Zajac Hines et al., Left to Their Own Devices: Breakdowns in United States
Medical Device Premarket Review, 7(7) PLOS MED. (2010).
95 Id. at 3.
96
Id.
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lenient interpretation of this term.97 Even though the agency asserts
that it possesses the “scientific expertise [that] enables [the agency] to
exercise considerable discretion in construing intended uses,” the FDA
has permitted more novel devices to be reviewed under the 510(k)
pathway.98 Additionally, differences in technological characteristics of
a predicate device and a new device do not preclude a determination
of substantial equivalence, as long as the differences do not raise new
issues of safety or effectiveness.99
D. European Union Medical Device Regulation (EU MDR)
Structure
For manufacturers interested in the European market, medical
devices will not be approved for commercialization without
conforming to strict European Commission safety requirements.100
One of the most important requirements is the affixation of the
Comformité Européenne (French for ‘European conformity’) (CE)
mark.101 Instead of a national agency overseeing the regulatory process,
the EU medical device regulation responsibility belongs to the
Competent Authorities (CA), Notified Bodies (NB), and authorized
representatives.102 Although each member state may have their own
regulatory scheme for medical device approval, all member states in
the EU accept the CE mark and allow manufacturers to provide
minimal documentation to show the safety and efficacy of a device
before placing the product on the market.103

Id.
Id.
99 Id. at 4.
100 Id.
101
Regulation 2017/745 of the European Parliament and of the Council of
Apr. 5, 2017, art. 20, 2017 O.J. (L 117) (EU).
102
Elaine French-Mowat & Joanne Burnett, How Are Medical Devices Regulated
in the European Union?, 105(Suppl 1) J. ROYAL SOC’Y MED. S22, S24 (2012).
103
Besides the members states that are part of the EU, countries in the
European Economic Area (Norway, Liechtenstein and Iceland), Turkey, and
Switzerland are part of the EU single market for medical devices. This means that
these countries also accept the CE mark to show that the medical devices are
approved for commercialization. Medical Device Regulations: Global Overview and Guiding
Principles, WORLD HEALTH ORG. (2003).
97
98
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A Competent Authority is “any person or organization that has
the legally delegated or invested authority, capacity, or power to
perform a designated function.”104 A Competent Authority designates
a Notified Body to ensure that the conformity assessment procedures
are completed according to the EU Medical Device Regulations
(MDR).105 The role of a Notified Body is to conduct a conformity
assessment under the relevant EU Directives.106 Another vital player in
conformity assessments is the authorized representative. The
authorized representative is designated by medical device
manufacturers and is legally responsible for compliance with the MDR
and serves as the first point of contact for the EU authorities.107 The
Competent Authority, Notified Body, and authorized representatives
each have a precise scope of actions and responsibilities, as listed in
the EU MDR.108
The term “medical device” as defined in the EU MDR is
similar to the FDA definition.109 Like the FDA, the EU regulations
place medical devices into four categories: Class I (including Class Is
and Im), Class IIa, Class IIb, and Class III. The higher the
classification, the greater the level of assessment required by Notified
Bodies (NB).110 The intended purpose of the device determines the
Want to Know More About the Notified Body?, BSI GROUP,
https://www.bsigroup.com/globalassets/meddev/localfiles/it-it/documents/bsiguide_to_notified_body_2019-it.pdf (last visited Apr 15, 2022).
105
French-Mowat & Burnett, supra note 102, at S23.
106
BSI Group, supra note 104.
107
French-Mowat & Burnett, supra note 102, at S23.
108
Regulation 2017/745 of the European Parliament and of the Council of
Apr. 5, 2017, art. 10, 2017 O.J. (L 117) (EU).
109
Medical device is defined as “any instrument, apparatus, appliance,
material or other article, whether used alone or in combination, including software
necessary for its proper application intended by the manufacturer to be used for
human beings for the purpose of: diagnosis, prevention, monitoring, treatment or
alleviation of disease; diagnosis, monitoring, treatment, alleviation of or
compensation for an injury or disability; investigation, replacement or modification
of the anatomy or of a physiological process; control of conception, and which does
not achieve its principal intended action in or on the human body by
pharmacological, immunological or metabolic means, but which may be assisted in
its function by such means.” Regulation 2017/745 of the European Parliament and
of the Council of Apr. 5, 2017, art. 2, 2017 O.J. (L 117) (EU).
110
French-Mowat & Burnett, supra note 102.
104
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device classification, not the technical characteristics of the device.111
There are several considerations for device classification, including the
duration of contact with the human body, the degree of invasiveness,
and local versus systemic effect of the device on the human body.112
Manufacturers have the responsibility to ensure that their
device complies with the relevant EU legislation’s essential
requirements.113 Each medical device class is required to prepare
technical documentation that is submitted to the Notified Body for
certification as part of the CE marking process.114 Manufacturers must
follow certain conformity assessment procedures, like design
verification and validation, human factors engineering studies, or
clinical evaluation, depending on the device’s risk.115 The procedures
help manufacturers decide how much information is needed to
support their claims of the safety and efficacy of their device.116 The
CE mark signifies that the device meets all the appropriate provisions
of the relevant legislation,117 and indicates that the device can be freely
marketed anywhere in the European Economic Area (EEA) without
further regulatory control.118
Similar to FDA regulations for Class II devices, the EU also
uses the equivalent device standard.119 Instead of using this standard
for a certain class of devices, the EU MDR allows the show of
equivalency for non-clinical and clinical data regardless of the
classification of the device.120 However, unlike the FDA, the EC does
not have a unified regulatory body that reviews equivalency of
Id.
Regulation 2017/745 of the European Parliament and of the Council of
Apr. 5, 2017, Annex II, 2017 O.J. (L 117) (EU).
113
Regulation 2017/745 of the European Parliament and of the Council of
Apr. 5, 2017, art. 10, 2017 O.J. (L 117) (EU).
114
French-Mowat & Burnett, supra note 102, at S23.
115 Id.
116
Regulation 2017/745 of the European Parliament and of the Council of
Apr. 5, 2017, art. 10, 2017 O.J. (L 117) (EU).
117 Id.
118
French-Mowat & Burnett, supra note 102, at S23.
119
Regulation 2017/745 of the European Parliament and of the Council of
Apr. 5, 2017, art. 5, 2017 O.J. (L 117) 1 (EU).
120 Id.
111
112
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devices.121 This burden falls on registered notified bodies.122 Medical
device manufacturers are responsible for engaging with a registered
notified body before they may commercialize their devices in the
European market.123 Issues identified for FDA’s substantial
equivalence standard also exist for the EU equivalent device standard,
including the lack of clarity and consistency in defining what
constitutes an “equivalent device.”124
E. Intellectual Property Law in the United States and the European
Union and Issues with Patentability for Artificial IntelligenceBased Medical Devices
Intellectual property law in the United States, specifically
copyright and patent law, is permitted by the U.S. Constitution,125
which explicitly grants Congress power to “[p]romote the [p]rogress”
of the relevant field and the ability to create copyright and patent law.126
For trademarks and other forms of intellectual property, the federal
government only has the authority to make law through the regulation
of commerce.127 It is widely understood that the Framers of the U.S.
Constitution grounded the idea of copyright and patent law for the
purpose of promoting economic benefit and increasing the amount of
innovation and creative works available to the people.128 Although the
federal government is active in intellectual property law, there are still
important state regulations.129

121
Travis G. Maak & James D. Wylie, Medical Device Regulation: A Comparison
of the United States and the European Union, 24 J. AM. ACAD. ORTHOPAEDIC
SURGEONS 537, 543 (2016).
122
Id. at 539.
123
World Health Organization, supra note 103.
124 Id.
125 Outline of the Legal and Regulatory Framework for Intellectual Property in the
United
States
of
America,
WIPO
IP
PORTAL,
https://wipolex.wipo.int/en/info/outline/US (last visited Jan. 19, 2020).
126
[The Congress shall have power] “[t]o promote the progress of science
and useful arts, by securing for limited times to authors and inventors the exclusive
right to their respective writings and discoveries.” U.S. CONST. art. VIII, § 8.
127 Id.
128
Legal and Regulatory Framework supra note 125.
129 Id.
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Congress delegated regulatory authority for intellectual
property to several agencies.130 The United States Patent and
Trademark Office (USPTO), under the Department of Commerce,
grants U.S. patents under the Patent Code, registers trademarks under
the Lanham Act, and hears certain disputes through either the Patent
Trial and Appeal Board (PTAB) or the Trademark Trial and Appeal
Board (TTAB).131 The Patent Code is contained in Title 35 of the
United States Code (USC).132 Patents are exclusively governed by
federal law. There are three types of patents that may be granted: utility
patents, design patents, and plant patents.133 Currently, the utility
patent term, starting from the earliest claimed filing date, is twenty
years.134 However, this timeline may be extended to accommodate for
delays in the patent office or to obtain FDA approval under the Drug
Price Competition and Patent Term Restoration Act.135
Fortunately for healthcare manufacturers the Food, Drug, and
Cosmetics Act (FDCA) also grants quasi-patent rights in the form of
market exclusivities for drugs.136 For example, the Orphan Drug
Id.
About Us, UNITED STATES PATENT AND TRADEMARK OFF.
https://www.uspto.gov/about-us (last visited Jan. 19, 2022).
132
35 U.S.C.A. § 100 (Westlaw through Pub. L. No. 116-259).
133 Manual of Patent Examining Procedure, UNITED STATES PATENT AND
TRADEMARK OFF., https://www.uspto.gov/patent/laws-and-regulations/manualpatent-examining-procedure (last visited Jan. 19, 2022).
134
35 U.S.C.A. § 154 (Westlaw through Pub. L. No. 116-259).
135
The Drug Price Competition and Patent Restoration Act, also known as
the Hatch-Waxman Amendments, established the approval pathway for generic drug
products, under which applicants can submit an abbreviated new drug application
(ANDA) under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C
Act).
Hatch-Waxman
Letters,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatchwaxman-letters (last updated July 19, 2018).
136
The laws of the United States are organized by subject into the United
States Code. The United States Code contains only the currently enacted statutory
language. The official United States Code is maintained by the Office of the Law
Revision Counsel in the United States House of Representatives. The Office of the
Law Revision Counsel reviews enacted laws and determines where the statutory
language should be codified related to its topic. The Federal Food, Drug, and
Cosmetic Act and subsequent amending statutes are codified into Title 21 Chapter 9
of the United States Code. Federal Food, Drug, and Cosmetic Act (FD&C Act), U U.S.
FOOD & DRUG ADMIN., https://www.fda.gov/regulatory-information/laws130
131
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Designation program grants “orphan status” to drugs and biologics,
where “orphan status” is defined as “those intended for the treatment,
prevention or diagnosis of a rare disease or condition, which is one
that affects less than 200,000 persons in the United States or meets
cost recovery provisions of the act.”137 Once a drug is designated as an
orphan drug, the FDA will grant market exclusivity of the drug due to
the drug’s intended use of treating rare diseases.138 For example, from
2014 to 2016, there were eleven cases of ebolavirus infections in the
United States.139 On May 8, 2019, the FDA designated EBANGATM as
an orphan drug intended for the treatment of infection caused by the
Zaire ebolavirus in adult and pediatric patients, including neonates
born to a mother who is tested positive for the Zaire ebolavirus
infection.140 EBANGATM received market approval from the FDA on
December 21, 2020.141
The European Union acts as a single market instead of as a
collection of individual countries.142 As an EU member, each country
has a right to transfer and implement the laws and regulations
promulgated by the EU.143 Intellectual property law is included in that
regulatory design. The European patent system is considered the home
of the world patent system.144 The European Patent Office (EPO) is
enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act (last updated Mar. 29,
2018).
137 Developing Products for Rare Diseases & Conditions, U.S. FOOD & DRUG
ADMIN.,
https://www.fda.gov/industry/developing-products-rare-diseasesconditions (last updated Dec. 20, 2018).
138 Designating an Orphan Product: Drugs and Biological Products, U.S. FOOD &
DRUG ADMIN., https://www.fda.gov/industry/developing-products-rare-diseasesconditions/designating-orphan-product-drugs-and-biological-products (last updated
Apr. 6, 2020).
139 2014-2016 Ebola Outbreak in West Africa, CNTR. FOR DISEASE CONTROL
&
PREVENTION,
https://www.cdc.gov/vhf/ebola/history/2014-2016outbreak/index.html (last updated Mar. 8, 2019).
140 Search Orphan Drug Designations and Approvals, U.S. FOOD & DRUG
ADMIN., https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
(last visited Jan. 19, 2022).
141 Id.
142 Single
Market
and
Standards, EUROPEAN
COMM’N,
https://ec.europa.eu/growth/single-market_en (last visited Jan. 19, 2022).
143 Id.
144 Id.
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responsible for the search, examination, and authorization of
European patents.145 The requirements of patentability are similar to
those in the United States insofar as the invention must satisfy several
requirements—being novel, involving inventive procedure, being
capable of industrial application, and not otherwise being excluded
from patentability.146
A big concern for manufacturers, both in the United States and
the EU, is whether the device passes the novelty threshold to meet
patentability requirements.147 When medical device manufacturers
commercialize their device using the substantial equivalence standard
in the United States, or equivalent device standard in the EU,
manufacturers may not be able to differentiate their device from an
existing device enough to have a novelty hook to render the device
patentable. On average, manufacturers are expected to spend $31
million to bring a medical device to market through the 510(k)
pathway.148 The time and cost required to bring a device to market is a
major incentive for manufacturers to also ensure its patentability to
secure exclusive rights of the device for a set patent term.149 This
exclusive right will allow the patent owner to recoup any research and
development costs and obtain a return on investment, which allows
the manufacturer to gain competitiveness in the market.150

Patent
Protection
in
the
EU,
EUROPEAN
COMM’N,
https://ec.europa.eu/growth/industry/policy/intellectual-property/patents_en
(last visited Jan. 19, 2022).
146 Patentability Requirements, JUSTIA, https://www.justia.com/intellectualproperty/patents/patentability-requirements/ (last updated June 2019).
147
Xirui Zhang et al., The Interplay Between the FDA Regulatory Process for Medical
Devices and Patent Law—Considerations for 510(k) Submission, FINNEGAN (Aug. 4, 2020),
https://www.finnegan.com/en/insights/blogs/ip-fda-blog/the-interplay-betweenthe-fda-regulatory-process-for-medical-devices-and-patent-law-considerations-for510k-submission.html.
148
Danielle Kirsh, Exploring FDA Approval Pathways for Medical Devices, MASS
DEVICE (Sept. 12, 2019), https://www.massdevice.com/exploring-fda-approvalpathways-for-medicaldevices/#:~:text=The%20average%20cost%20to%20bring,average%20costs%20o
f%20%2494%20million.
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Evoluted New Media, The Importance of Patents, LABORATORY NEWS (July
1, 2005), https://www.labnews.co.uk/article/2029687/the_importance_of_patents.
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Another potential issue is that a 510(k) submission for the
device might be considered prior art.151 Prior art constitutes those
references or documents which may be used to determine novelty and
non-obviousness of claimed invention in a patent application.152 Prior
art does not need to exist physically or even be commercially available;
it is sufficient that someone, somewhere, sometime previously has
described or shown or made something that contains a use of
technology that is very similar to a manufacturer’s device.153 35 U.S.C.
102(a) describes prior art as any “claimed invention that was patented,
described in a printed publication, or in public use, on sale, or
otherwise available to the public before the effective filing date of the
claimed invention.”154 Because a summary of a 510(k) submission is
usually published and available on the FDA 510(k) database, it may be
considered as prior art.155
The third potential issue is that the 510(k) submission of
substantial equivalence information could be seen as an admission of
infringement.156 When submitting a 510(k), manufacturers usually
identify a predicate device to conduct a substantial equivalence
comparison with the manufacturer’s own device.157 Increasing the
number of similarities found between the predicate device and the
manufacturer’s device increases the chances of clearance from the
FDA. However, more similarities between the predicate device and the
manufacturer’s device has the inverse outcome in terms of
patentability. Patent infringement rests on “making, using, offering to
sell, or selling something that contains every element of a patented

Zhang et al., supra note 147.
USPTO regularly publishes presentations to explain the process of a
patent or trademark application. This presentation describes how to understand prior
art and how to use it in determining patentability. Fenn Mathew, Understanding Prior
Art and Its Use in Determining Patentability, UNITED STATES PATENT AND TRADEMARK
OFFICE.
https://www.uspto.gov/sites/default/files/documents/May%20Info%20Chat%20
slides%20%28003%29.pdf.(last visited Nov. 17, 2020).
153 Id.
154
MPEP § 2152 (9th ed. Rev. 10.2019, June 2020).
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Zhang et al., supra note 147.
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claim or its equivalence while the patent is in effect.”158 Precluding
prior permission of the patent owner, manufacturers risk being
accused of infringement when their device is equivalent to an existing
device.159
The EU regulatory field also presents similar issues. According
to the EU MDR, manufacturers must identify an equivalent device, but
the regulations do not define any parameters for determining
equivalence.160 The EC has published a guidance document to
distinctly identify the criteria for evaluation of an equivalence device
to be used as clinical evidence.161 However, manufacturers are still at a
loss for the various situations not discussed in the guidance
document.162 In situations where equivalent devices are not CE marked
or sold in Europe, comparison of equivalency is generally not
accepted.163 Manufacturers would have to present a strong argument
to their Notified Body on the reasons why the data is transferrable to
a European population and manufacturers would have to conduct a
safety and efficacy analysis for any gaps related to clinical
performance.164
Additionally, in situations where technological composition is
spread across multiple devices or no discussion of any differences
between equivalent device and new device, manufacturers might have
difficulty in preparing a comprehensive equivalency comparison.165
Because the MDR mandates that the device being claimed as the
equivalent device must share the same technical, biological and clinical
characteristics, manufacturers may have difficulty in collecting enough
data to support the equivalency comparison.166 Usually, technical,
biological and clinical characteristics are considered confidential
35 U.S.C.A. § 271 (Westlaw through Pub. L. No. 116-259).
Zhang et al., supra note 147.
160
MDCG 2020-5 Clinical Evaluation - Equivalence, EUROPEAN
COMMISSION, https://ec.europa.eu/docsroom/documents/40903?locale=en (last
visited Apr 15, 2022).
161
Id.
162
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163 Id.
164 Id.
165 Id.
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proprietary information of a company that will not be shared between
competitors, barring signed intercompany license agreements or
mergers and acquisition of companies.167
These issues in the United States and the EU are amplified
when applied to AI/ML-based SaMD because of the unique features
of artificial intelligence. Manufacturers have a strong interest in
maximizing their AI property interest and easily commercializing their
product to generate revenue. This article will attempt to fill in the gaps
of the lack of regulations for AI/ML-based SaMD and to reconcile the
interplay between a substantial equivalence or equivalent device
standard and potential success for patentability.
III. ANALYSIS
A. Comparative Analysis between the United States and the
European Union
1. Medical Device Regulations
To design the most effective commercialization pathways for
AI/ML-based SaMD, it is essential recognize the differences in
medical device regulation in the United States and the EU to identify
any potential gaps in the regulatory framework. In addition to
extensive literature comparing these differences, there is also political
pressure for a substantial reform of better regulations and further
research to understand the effectiveness of both the United States and

Confidential business information is defined as “information which
concerns or relates to the trade secrets, processes, operations, style of works, or
apparatus, or to the production, sales, shipments, purchases, transfers, identification
of customers, inventories, or amount or source of any income, profits, losses, or
expenditures of any person, firm, partnership, corporation, or other organization, or
other information of commercial value, the disclosure of which is likely to have the
effect of either impairing the Commission’s ability to obtain such information as is
necessary to perform its statutory functions, or causing substantial harm to the
competitive position of the person, firm, partnership, corporation, or other
organization from which the information was obtained, unless the Commission is
required by law to disclose such information. The term ‘confidential business
information’ includes ‘proprietary information’ . . . ” 19 C.F.R. § 201.6 (2020).
167
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EU regulatory systems.168 Regulations for AI/ML-based SaMD could
be the trigger for a regulatory overhaul for both the United States and
EU. Because there is a global interest in harmonizing medical device
regulations, the proposed regulations in this article will have to take
into account that interest.169 To ensure the success of regulations,
global regulators must have foresight into the future of medical
technology.
The differences in device regulations in the United States and
the EU fall into six categories: purpose of the regulations, structure of
the regulations, funding received, data requirement for device
approval, premarket transparency, and the type of post-market device
surveillance.170 While the FDA—a government agency mandated to
protect the public’s health—clears and approves medical devices for
commercialization in the United States, NBs—which are private
companies—regulate device approval in the EU.171 172 Some experts
have questioned whether notified bodies are more interested in getting
devices to market rather than in protecting the health and safety of the
public because they are privatized,173 although the FDA also receives
its own fair share of criticism. Many critics both inside and outside the
agency have said that the FDA’s standards have been continually
declining.174 Critics think there are too many prescription drugs and
medical devices being approved with too little data on how safe or
efficacious they are.175 Part of the problem is that the agency has too
few resources and too little power to fulfill its key responsibilities.176
While the FDA regulates device approval and surveillance
under one centralized agency, there are more than seventy notified

Maak & Wylie, supra note 121 at 543.
International Medical Device Regulators Forum (IMDRF), supra note 11.
170
Maak & Wylie, supra note 121 at 542.
171 Id. at 538.
172
Maak & Wylie, supra note 121 at 538.
173 Id. at 539.
174 The F.D.A. Is in Trouble. Here’s How to Fix It., N.Y. TIMES (Feb. 11, 2020).
https://www.nytimes.com/2020/01/11/opinion/sunday/fda-commissionerstephen-hahn.html.
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168
169

258

2022 Artificial Intelligence/Machine Learning-Based Medical Devices

10:2

bodies that regulate device approval in the EU.177 Notified bodies are
also completely funded by private contracts with device manufacturers,
while U.S. federal appropriation provides for more than eighty percent
of FDA funding.178 User fees during the application process contribute
the remaining twenty percent of FDA funding.179 Historically, the
FDA has been chronically underfunded, leading to issues with the
agency being able to meet its statutory responsibilities in a timely and
acceptable manner.180 At its current pace, the FDA would take roughly
twenty-seven years to check every international medical device plant.181
In addition to FDA’s existing responsibility, Congress has been passing
more than a hundred statutes that have added new responsibilities over
the past twenty years without providing enough resources to carry out
these tasks; consequently, the FDA has been overwhelmed and falling
behind on its duties.182 Increased FDA funding would likely lead to a
more efficient drug, medical device, and food approval process, and
enable the agency to better protect public health.183
The largest apparent difference between the U.S. and EU
systems concerns the substantive part of the regulations.184 For a
device to be cleared or approved in the United States, a device must
prove to be substantially equivalent to a predicate device through a
510(k) clearance or prove to be safe and efficacious through the
premarket authorization approval.185 The EU regulations only require
proof that the device can perform its intended function and
manufacturers are able to use an already CE-marked equivalent device
Maak & Wylie, supra note 121, at 539.
Id. at 542.
179 Id.
180 Federal Funding for the U.S. Food and Drug Administration (FDA), ACAD. OF
MANAGED
CARE
&
PHARM. (Aug.
2013).
https://amcp.org/sites/default/files/201902/Federal%20Funding%20for%20FDA_August2013.pdf.
181 The F.D.A. in Crisis: It Needs More Money and Talent, N.Y TIMES (Feb. 3,
2008).
https://www.nytimes.com/2020/01/11/opinion/sunday/fdacommissioner-stephen-hahn.html.
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as proof.186 Manufacturers have an easier pathway to approval in the
EU due to the lower standard needed for approval.187 In addition to an
easier pathway, the EU processes also generally take a shorter time
from submission to approval.188 This is generally due to the more
personal relationships that manufacturers have with their chosen
notified bodies, compared to the lack thereof with the FDA.189
Premarket transparency is another important difference
between the United States and EU regulatory systems.190 Many device
manufacturers rely on substantial equivalency in the United States to
obtain clearance to market their device.191 Although there are
proprietary limits that exist for sharing information of a device, the
FDA regularly publishes 510(k) summaries authored by
manufacturers.192 These 510(k) summaries are available on the FDA
510(k) searchable database and manufacturers regularly use these
summaries as part of their substantial equivalency analysis.193 In
contrast, approval decisions of the notified bodies are not made public
at all.194 Manufacturers in the EU have to rely on information of
equivalent devices that is available on public domain sites to conduct
their equivalency analysis, which ties into concerns of patentability as
information on public domain sites would be considered prior art.195
Lastly, medical device regulation does not just end with
premarket review; regulators are responsible for post-market device
surveillance as well196 through mandatory manufacturer reporting to
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the FDA.197 The FDA can issue public health advisories, safety alerts,
and product suspensions or withdrawals through a recall process.198 In
the EU, manufacturers must submit adverse events to competent
authorities.199 Post-market data are shared among competent
authorities but not with the public.200 Competent authorities are
responsible for issuing adverse event reports and field safety notices or
device recalls.201
Understanding the core differences between U.S. and EU
medical regulations is vital when developing a new regulatory
framework for an upcoming industry like AI/ML-based SaMD. It is a
chance for regulators to address existing gaps while developing more
efficient regulatory frameworks for the future of medical devices.
Because of the political pressure to substantially overhaul the existing
regulatory framework, this could also be the first step in creating a
harmonized medical device regulation system globally. As far as
regulators are concerned, harmonized regulations are needed because
they reduce redundant reviews, create an opportunity to share
information on product safety, and result in a more efficient regulatory
regime.202 The net result will allow for improved trade in medical
devices and safer products for the public.203
a.

Shortcomings of Current United States and European Union
Medical Device Regulations

Unsurprisingly, criticism surrounding the medical device
regulations in the United States and in the EU abounds.204 A recent
analysis has revealed an uptick in the number of medical device recalls
in the United States and an increase in the number of manufacturer
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field safety notices in the United Kingdom over the past few
decades.205 This situation reflects a very low standard that is currently
used to gain regulatory approval.206 510(k) pathways do not require any
clinical trials; the manufacturer is only required to demonstrate
substantial equivalency to another device on the market.207 The EU
also uses the predicate of equivalence for device regulation.208 The
biggest problem is that the definition of “equivalence” is interpreted
so loosely that even the FDA admits they need to “clarify the meaning
of ‘substantial equivalence.’”209
A consequence of the loose definition of “substantial
equivalence” can be seen with the Medtronic MiniMed Insulin
Pump.210 On February 12, 2020, the FDA issued a Class I recall for the
Medtronic MiniMed Insulin Pump because its use had caused serious
injuries and even one death.211 Insulin pumps are Class II devices and
Medtronic went through the 510(k) process to obtain market
authorization, meaning that Medtronic was able to use the “substantial
equivalence” standard to obtain market clearance for
commercialization.212 Without a firm definition of “substantial
equivalence,” serious injuries—and death—have occurred in these
Class II insulin pumps.213 This small example exemplifies the need for
a clear cut definition.
Particularly concerning is that there are many issues with
medical devices that go unnoticed by the appropriate agencies.214
Currently, in the United States and the EU, there is limited ability to
trace most medical devices, so when problems or recalls occur, it can
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be impossible to understand the magnitude of the problem without the
appropriate traceability and post-market surveillance activities.215 The
additional requirement of patient data privacy and security will also
contribute to the vulnerabilities of the current regulatory framework as
the appropriate requirements to ensure safety and efficacy are not
established and upheld.216 Furthermore, the public’s demand for
accessible and transparent information about devices and the
regulatory process has grown in the recent years, and both the United
States and EU must take action to improve the exchange of
information.217 These issues can be resolved with a more robust
medical device regulation system that is harmonized between the
countries.218 This solution is especially crucial for the formation of
AI/ML-based SaMD regulations due to the lack of understanding and
transparency of a fully software based medical device.
2. Patent Law
Intellectual property law in the United States and the EU
includes applications for hardware and software products. Software
patents are notoriously difficult to obtain.219 The USPTO and the EPO
do not see software-related patents in the same way, creating another
layer of complexity for AI/ML-based SaMD.220 According to the
European Patent Convention (EPC), a patent can be granted in any
field.221 However, the EPC does not consider computer programs to
be inventions if they are claimed as such, and methods for performing
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mental acts, playing games, doing business and presenting information
are excluded from patentability altogether.222 However, under this
approach, a claim directed to a computer program will not be excluded
from patentability under Article 52 of the EPC if it contains at least
one feature considered to have technical character.223 Therefore, it is
sufficient that a claim is directed to a device or a method implemented
in a computer to avoid exclusion from patentability.224 The nontechnical features of such a claim will be ignored when assessing an
inventive step.225
The EPC provides no general definition of what is considered
technical, but relevant case law before the EPO Board of Appeals gives
some indication of what constitutes “technical character.”226 For
example, a claim to a computer program running in a computer is not
considered excluded from patentability if it provides further technical
effect going beyond the computer’s normal capabilities.227 Similarly,
data encoding schemes contained in physical mediums are traditionally
considered to have “technical character.”228 But “technical character”
should refer to more functional data, which serves to control the
operation of device, rather than cognitive data, the content and
meaning of which are relevant to human users only.229 Ultimately, the
technical assessment is highly subjective and has been subject to
substantial patent agent and examiner arguments.230
In contrast with the U.S. patent system, patent protection for
software-related inventions differ significantly from the EPO
approach, both in terms of scope of eligibility and in how the
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determination is made.231 The threshold requirement for patent
protection is set out in 35 U.S.C. § 101, which defines “patentable
subject matter.”232 Depending on how the patent claim is framed, a
software-related invention could easily fall into one or more of the
patentable subject matter categories.233 For example, a claim for
software, presented as a process claim, would pass the baseline for
patent eligibility.234 The United States Supreme Court has further
outlined the breadth of patentable subject matter and its exceptions.235
Judicial exceptions include abstract ideas, natural phenomena, and laws
of nature.236 Applications supposedly involving a judicial exception are
seemingly subject to more front-end scrutiny during the examination
process, meaning much more emphasis seems to be placed on the
analysis of whether applications are patentable subject matter rather
than the evaluation of other requirements of patentability.237
As an example, the U.S. Supreme Court decision in Alice v. CLS
Bank serves as a foundation for determining whether a softwarerelated invention is considered an “abstract idea.”238 Using the Alice
test, it is first determined whether the invention at issue is directed at
a patent-ineligible concept and then determined whether the
invention’s elements, considered both individually and as an ordered
combination, transform the nature of the claims into an eligible
patent.239 This assessment focuses on patentable subject matter, as
opposed to other patentability doctrines. In 2019, USPTO Director
Andrei Iancu issued guidelines more favorable to patent applicants
with software-related inventions.240 The guidelines separated the first
part of the Alice test into two prongs.241 The first prong is to determine
if the patent claim is actually a judicial exception.242 Where the claim is
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a judicial exception, the second prong then determines whether the
judicial exception is used for a practical application, and if so, the claim
is still patent eligible.243 Even if the patent elements do not transform
the nature of the claim and the claim is considered to be wellunderstood, routine, or conventional, the invention is still patent
eligible as long as there is a practical application.244
The key difference between EPO and the USPTO is that the
EPO requires further technical effect for software-related
inventions.245 Contrasting that idea with the USPTO, if an abstract idea
is claimed in the United States, it must be tied to a practical application
of the idea.246 Additionally, improvements in the function of a
computer that are not understood, routine, or conventional in the
industry may be evidence that the invention is patent eligible in the
United States.247 The differences between EPO and USPTO can cause
confusion for applicants looking to patent their AI/ML-based SaMD,
especially manufacturers interested in expanding their business and
protecting their intellectual property globally.
a.

Shortcomings of Current United States and European Union
Intellectual Property Law, Specifically Patent Law

Even though the EPO and the USPTO differ on several key
measures, when it comes to patent prosecution, these two systems
share basic features common to all patent systems internationally.248
Notably, these two governmental agencies grant exclusive propertylike rights.249 These rights are privately enforced and rely on national
courts and agencies to assist with the interpretation of the system and
rules for enforcement.250 Infringement issues are also dealt through the
court system that may conduct a full investigation into patent
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validity.251 Both the EPO and the USPTO systems are considered to
be “unitary” to the extent that the law does not normally distinguish
among different types of technology.252
Given the similar foundation of the structure for both patent
systems, it is not surprising that these two system share the same
fundamental issues.253 While the goal of the patent system is to
propagate innovation and stimulate the economy, the patent
administration and practice is considered to be legal and processorientated.254 This creates a tension when trying to completely overhaul
the patent system to accommodate the emerging field of artificial
intelligence.255 The technical nature of patent law and the private nature
of patent enforcement causes difficulty for non-practitioners to
contribute to policy developments, leaving those who manage the
process to retain control of evolving rules and regulations.256 Although
the patent office claims no responsibility for how patents work after
they have been issued, policymakers routinely look to the patent office
for policy advice.257 The office then tends to turn to patent
professionals and applicants for substantive policy and patent
administration advice.258 Therefore, patent system reform generally
would favor interests and perspectives of the industries most
benefitted by patents or by the largest customers that hold huge patent
portfolios.259
Another issue is related to the gap between socio-economic
goals of the patent system and its legal-procedural structure.260 Unlike
other regulatory regimes, patent policy development remains oriented
to application of the already established case law in individual cases.261
The eligibility of software has been rarely addressed in the courts or in
251
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legislation, creating unclear expectations for inventors when trying to
pursue a patent.262 Issues will undoubtedly arise when AI/ML-based
SaMD manufacturers attempt to obtain a patent on their software
while pursuing market authorization from regulatory bodies. Because
agencies that regulate medical devices have an underlying goal to
improve the safety and efficacy of medical products for the public,263
decisions made by regulatory agencies are intertwined with socioeconomic implications, while patent systems are not.264 Therefore, the
disjoint between the patent systems and the regulatory systems may
create complications for manufacturers when determining
requirements needed for a commercialization pathway.
B. Proposal for New Regulations for Artificial Intelligence/Machine
Learning-Based Software as a Medical Device in the United
States and the European Union
Despite the differences between the U.S. and the EU medical
device regulatory framework, both jurisdictions could benefit from
similar solutions to produce a more effective medical device regulation
to remedy three key issues: inconsistent evidence requirements during
the application process, lack of proper traceability and post-market
surveillance requirements, and lack of transparent and accessible
device information to the public.265
U.S. and EU medical device regulations have historically
created the wrong incentives for manufacturers to generate the
evidence needed to better understand and evaluate the benefits and
risks of new devices.266 On average, depending on the level of risk for
the medical device, a clinical study would cost manufacturers
approximately $12 million.267 Considering the equivalency standard
used in both jurisdictions, many manufacturers would be
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understandably reluctant to undertake new clinical studies when they
can rely on already cleared devices to establish equivalency to a
predicate device.268 This suggests that when a medical device enters the
market, the information about its safety and efficacy is limited, at best.
Once the device enters the market, manufacturers are
technically responsible for conducting proper traceability and postmarket surveillance activities to ensure that their device does not create
any adverse events.269 Manufacturers are required by law to report any
serious adverse events or deaths, but they are not required to do so if
they have justification that the events are unrelated to their device.270
Without systemic post-market data collection, it is extremely difficult
for health professionals and regulatory agencies to understand where
the device is located and what the actual outcome of the device is once
they are on the market.271
Consequently, achieving an open and accessible information
exchange between the public and the regulatory agencies is still
intangible.272 Manufacturers’ applications for a new device remains
confidential, as well as information regarding the reasons why devices
are not cleared or approved.273 Moreover, in the EU, Notified Bodies
are not required to publish their decision-making processes, any
evidence provided by manufacturers, or the basis on which a CE mark
was granted.274 Post-market data is also not shared with the public.275
Adequate and transparent information on the benefits and risks of new
devices must be assured so the public can become more informed on
the use of new devices.276
To step into the right direction of medical device regulatory
reform and to include the AI/ML-based SaMD industry, regulators
should look to other regulatory agencies for guidance. For example, in
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2018, the U.S. Federal Communications Commission (FCC) was
proactively looking into applications of AI/ML in the industry.277 At
that time, FCC Chairman Ajit Pai introduced a series of forums on
artificial intelligence and machine learning in hopes of learning more
about the advancement of the technology and its effects on the
communications industry.278 Similarly, the EU has gathered an expert
group on artificial intelligence to advise on challenges and
opportunities during the legislative process.279 Not only do the U.S.
and EU medical device regulators need to design a more robust
medical device regulatory framework based on the inadequacy of the
current system, both jurisdictions could also benefit from looking
laterally into other industries for guidance.
C. Jumping Over the Patentability Hurdle for Artificial
Intelligence/Machine Learning-Based Software as a Medical
Device
Besides identifying the most efficient commercialization
pathway for devices, manufacturers generally have a strong interest in
protecting their intellectual property.280 Medical device manufacturers
face an interesting dichotomy when it comes to protecting their
proprietary information and receiving market authorization for their
devices. On one hand, manufacturers need to keep their proprietary
information to prevent infringement from others; on the other hand,
manufacturers need to balance the level of information provided to
regulatory agencies to make sure there is sufficient evidence for market
authorization.281 However, before manufacturers can make these
business strategy decisions, they would still have to overcome the
patentability hurdle for AI/ML-based SaMD.
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Due to the established jurisprudence of patentable subject
matter, the abstraction of an idea presents one of the particular
challenges manufacturers of software-related inventions face (in terms
of whether the invention or claim qualifies as patent-eligible).282 Both
the EU and the United States have subjective views on which
inventions are considered patentable.283 Although interpretive case law
exists, many confusing discussions regarding patentability are still held
during the assessment for software inventions.284 In the EU, EPO
requires that the subject matter have a technical character and is first
assessed without reference to prior art.285 In the United States, the U.S.
Supreme Court’s test in Alice serves as the foundation for all softwarerelated patent eligibility inquiries to determine whether the invention
is considered an “abstract idea.”286
Both jurisdictions do not have well-established definitions on
what kind of software is considered to be patent eligible, therefore,
more conversations between legislators are required to reform the
patent system to include AI/ML.287 The EPO took a step in the right
direction in late 2018 when the Office amended its examination
guidelines to include a specific section on how patent examination
principles apply to inventions relating to AI/ML.288 The guidance
emphasized that a mathematical method may contribute to technical
effect serving a technical purpose by application to a field of
technology or by adaptation to specific technical implementation.289
Furthermore, if computation models can be “trained” to serve a
technical purpose, the steps to generate the training set may also
contribute to the technical character of the invention, hence, making
the invention patent eligible.290 Similarly, in the United States, the
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USPTO provided guidance in 2019 on inventions relating to
mathematical models, organization of human activity methodology,
and human mental processes.291 This guidance encompasses
inventions relating to AI/ML as well and the USPTO advises
manufacturers to make sure that patent applications have clear, real
world technical applications to meet the patent eligibility threshold.292
D. A Glimpse into the Future for Artificial Intelligence/Machine
Learning-Based Software as a Medical Device in the United
States and the European Union
It is encouraging for manufacturers that the United States and
the EU are slowly ramping up discussions relating to AI/ML-based
inventions and adapting to the evolving field. In order to truly allow
for the expansion of the artificial intelligence industry, legislators and
industry professionals will need to gain better insight into the
requirements and goals of the overall patent system.293 Additionally,
legislators should consider the economic impact of patent decisions,
similar to how the medical device regulatory agencies operate.294 Seeing
how interconnected the medical device regulatory system and the
patent system are, it is in the best interest of legislators to integrate
intellectual property considerations into the medical device regulatory
framework, and vice versa. Finally, utilizing the role of IMDRF,
legislators globally can convene in one central forum to discuss the
reforming process of the current regulatory framework with the help
of experts in the artificial intelligence industry.
IV. CONCLUSION
On both sides of the Atlantic Ocean, the United States and EU
have an established history of medical device regulations.
Understanding and comparing the regulations are critical to
comprehending patentability because, in order for medical devices to
be cleared for commercialization or approved for market,
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manufacturers need to use a “substantial equivalence” standard in the
United States and an “equivalent device” standard in the EU.295 These
standards impact the United States and EU patentability laws because
it is unclear whether these medical devices, although ready for
commercialization, are novel or inventive enough to clear the
threshold for patentability.
Since artificial intelligence and machine learning in the
healthcare space are relatively new, there are not many regulations
relating to AI/ML-based SaMD. Currently, the FDA only has guidance
documents related to AI/ML-based SaMD, but no final promulgated
regulations.296 The EC recently published its new Medical Device
Regulations (MDR),297 but the MDR only has provisions for general
SaMD and has not included any provisions related specifically to
AI/ML-based SaMD.
There are several potential pathways for AI/ML-based SaMD
regulations to address the specific issues currently posed by the U.S.
and EU regulatory network. Regulators need to determine clear and
adequate evidence requirements during the application process, proper
traceability and post-market surveillance requirements, and transparent
and accessible device information to the public.298 Furthermore, both
the EU and the United States have subjective views on what invention
is considered to be patentable in their patent system.299 Although there
is case law to show judicial opinion, many confusing discussions are
still held during the assessment for software inventions.300 More
conversations between legislators are required for a patent system
reform for inclusion of AI/ML and realignment of the overall purpose
of the patent system based on economic analysis.301
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On top of commercialization success, many manufacturers are
interested in obtaining intellectual property rights for their invention.
When manufacturers use the substantial equivalence standard,
manufacturers generally have a hard time finding a novelty hook to
pass the patentability test.302 This challenge is true for all medical
devices, hardware-based or software-based. Because like every medical
device, the functionality, the clinical validity, and the intended use of
the AI/ML-based SaMD would still be used to determine whether the
device will get cleared for commercialization, the impact on
patentability will still be similar. In conclusion, taking advantage of the
IMDRF forum, legislators from around the globe should feel
encouraged for a medical device regulatory reform with the integration
of intellectual property considerations for AI/ML-based SaMD.
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